Compare Bristol-Myers Squibb Co (BMY) vs Kraft Heinz Co (KHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Kraft Heinz Co — how do they compare? Bristol-Myers Squibb Co trades at $58.51 (market cap $116.30B), while Kraft Heinz Co trades at $25.44 (market cap $29.74B). The key difference: Bristol-Myers Squibb Co is far larger — about 3.9× Kraft Heinz Co's market cap, and Kraft Heinz Co pays the higher dividend (6.38%). Which is the better fit depends on your goals.
| BMY | KHC | |
|---|---|---|
Market Cap | $116.30B | $29.74B |
Sector | Health | Consumer Staples |
52-Week High | $62.37 | $28.94 |
52-Week Low | $42.60 | $21.21 |
Enterprise Value | $152.24B | $46.78B |
Dividend Yield | 4.42% | 6.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Kraft Heinz (KHC) trades at $25.23, up 1.53% with a bullish technical trend and strong recent earnings beats. The stock shows attractive valuation metrics with a P/E of 13.04 and P/B of 0.71, though profitability remains challenged with negative net income margins. Recent corporate restructuring aims to accelerate growth, while a 6.4% dividend yield provides income support. Cash flow trends have improved significantly from 2022's negative $2.4B to 2025's positive $1.46B.
The outlook remains cautious despite technical strength. While undervaluation and dividend yield offer appeal, persistent negative profitability and high debt levels pose significant risks. Analyst consensus is predominantly Hold with a $23.50 price target below current levels, suggesting limited near-term upside potential amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →
